SA53 MDM2 Inhibitor: Lamassu Biotech Reports Significant Progress, Favorable Safety Profile in Phase 1/2a Clinical Trial
Novel SA53 MDM2 Inhibitor Therapy Has Potential to be a Breakthrough in Genetically-Targeted Cancer Treatment CLEVELAND, OHIO, UNITED STATES, November 3, 2025 /EINPresswire.com/ -- Lamassu Biotech, a clinical-stage pharmaceutical company, today …